Classifying Alzheimer's Disease Neuropathology Using Clinical and MRI Measurements

被引:0
|
作者
Zhuang, Xiaowei [1 ,2 ,3 ]
Cordes, Dietmar [1 ,4 ]
Bender, Andrew R. [1 ]
Nandy, Rajesh [5 ]
Oh, Edwin C. [2 ,3 ,6 ]
Kinney, Jefferson [2 ,7 ]
Caldwell, Jessica Z. K. [1 ]
Cummings, Jeffrey [7 ]
Miller, Justin [1 ]
机构
[1] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV USA
[2] Univ Nevada, Interdisciplinary Neurosci PhD Program, Las Vegas, NV USA
[3] Univ Nevada, Lab Neurogenet & Precis Med, Las Vegas, NV USA
[4] Univ Colorado Boulder, Boulder, CO USA
[5] Univ North Texas Hlth Sci Ctr, Sch Publ Hlth, Dept Biostat & Epidemiol, Ft Worth, TX USA
[6] Univ Nevada, Sch Med, Dept Internal Med, Las Vegas, NV USA
[7] Univ Nevada, Sch Integrated Hlth Sci, Chambers Grundy Ctr Transformat Neurosci, Dept Brain Hlth, Las Vegas, NV USA
关键词
Alzheimer's disease-meta-ROIs; APOE genotype; in vivo amyloid status; machine learning; severe AD neuropathology; HIPPOCAMPAL ATROPHY; MILD; ASSOCIATION; SEVERITY;
D O I
10.3233/JAD-231321
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Computer-aided machine learning models are being actively developed with clinically available biomarkers to diagnose Alzheimer's disease (AD) in living persons. Despite considerable work with cross-sectional in vivo data, many models lack validation against postmortem AD neuropathological data. Objective: Train machine learning models to classify the presence or absence of autopsy-confirmed severe AD neuropathology using clinically available features. Methods: AD neuropathological status are assessed at postmortem for participants from the National Alzheimer's Coordinating Center (NACC). Clinically available features are utilized, including demographics, Apolipoprotein E(APOE) genotype, and cortical thicknesses derived from ante-mortem MRI scans encompassing AD meta regions of interest (meta-ROI). Both logistic regression and random forest models are trained to identify linearly and nonlinearly separable features between participants with the presence (N=91, age-at-MRI = 73.6 +/- 9.24, 38 women) or absence (N=53, age-at-MRI = 68.93 +/- 19.69, 24 women) of severe AD neuropathology. The trained models are further validated in an external data set against in vivo amyloid biomarkers derived from PET imaging (amyloid-positive: N=71, age-at-MRI = 74.17 +/- 6.37, 26 women; amyloid-negative: N=73, age-at-MRI = 71.59 +/- 6.80, 41 women). Results: Our models achieve a cross-validation accuracy of 84.03% in classifying the presence or absence of severe AD neuropathology, and an external-validation accuracy of 70.14% in classifying in vivo amyloid positivity status. Conclusions: Our models show that clinically accessible features, including APOE genotype and cortical thinning encompassing AD meta-ROIs, are able to classify both postmortem confirmed AD neuropathological status and in vivo amyloid status with reasonable accuracies. These results suggest the potential utility of AD meta-ROIs in determining AD neuropathological status in living persons.
引用
收藏
页码:843 / 862
页数:20
相关论文
共 50 条
  • [31] Neuropathology of Alzheimer's disease and other dementias
    Dickson, DW
    CLINICS IN GERIATRIC MEDICINE, 2001, 17 (02) : 209 - +
  • [32] Neuropathology of Alzheimer's disease: a critical update
    Jellinger, KA
    Bancher, C
    JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 1998, (54): : 77 - 95
  • [33] Variations in the neuropathology of familial Alzheimer’s disease
    Claire Shepherd
    Heather McCann
    Glenda Margaret Halliday
    Acta Neuropathologica, 2009, 118 : 37 - 52
  • [34] Gender differences in Alzheimer's Disease neuropathology
    Corder, E
    Ghebremedhin, E
    Taylor, M
    Thal, D
    Ohm, T
    Braak, H
    GERONTOLOGIST, 2003, 43 : 12 - 13
  • [35] Psychosis in Alzheimer's disease is associated with specific changes in brain MRI volume, cognition and neuropathology
    Almeida, Francisco C.
    Jesus, Tiago
    Coelho, Ana
    Quintas-Neves, Miguel
    Gauthreaux, Kathryn
    Teylan, Merilee A.
    Mock, Charles N.
    Kukull, Walter A.
    Crary, John F.
    Oliveira, Tiago Gil
    NEUROBIOLOGY OF AGING, 2024, 138 : 10 - 18
  • [36] Accuracy of clinical diagnosis of Alzheimer disease and clinical features of patients with non-Alzheimer disease neuropathology
    Rasmusson, DX
    Brandt, J
    Steele, C
    Hedreen, JC
    Troncoso, JC
    Folstein, MF
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 1996, 10 (04): : 180 - 188
  • [37] Using MRI to measure progression in Alzheimer's disease
    Fox, NC
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S562 - S562
  • [38] γ-Hydroxybutyrate (Xyrem) ameliorates clinical symptoms and neuropathology in a mouse model of Alzheimer's disease
    Klein, Christian
    Mathis, Chantal
    Leva, Geraldine
    Patte-Mensah, Christine
    Cassel, Jean-Christophe
    Maitre, Michel
    Mensah-Nyagan, Ayikoe G.
    NEUROBIOLOGY OF AGING, 2015, 36 (02) : 832 - 844
  • [39] Cerebrovascular disease and alzheimer's disease neuropathology in multiple sclerosis
    Kaplan, T.
    Ouyang, B.
    Stefoski, D.
    Shoemaker, T.
    Ko, M.
    De Jager, P.
    Nag, S.
    Bennett, D.
    Arvanitakis, Z.
    Morales, F. Sierra
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 330 - 330
  • [40] Microglia activation in the brain as inflammatory biomarker of Alzheimer's disease neuropathology and clinical dementia
    Xiang, Zhongmin
    Haroutunian, Vahram
    Ho, Lap
    Purohit, Dushant
    Pasinetti, Giulio Maria
    DISEASE MARKERS, 2006, 22 (1-2) : 95 - 102